ASCO ‘13 - Promise of Novel Targets/Technologies to Unfold At ASCO 2013
New cancer therapies are being developed through targeted approaches that can accelerate development of more efficacious, personalized treatments. Data from such novel targets or technologies (BTK/ PI3K/ PD-1/ next-generation mAbs or ENHANZE tech/ SMDCs / Oncolytic virus / BiTE) for Hematological Malignancies and Solid tumors will be highlighted at ASCO. These include Amgen’s T-VEC (PhIII), Blinatumomab (PhII/III); Gilead’s Idelalisib (PhIII); Regeneron’s REGN910 (SAR307746, PhI), REGN421 (SAR153192, PhI); Endocyte’s Vintafolide (SMDCs, PhII); Halozyme’s PEGPH20 (PhI); Infinity pharma’s IPI-145 (PhI/II); Pharmacyclics’ Ibrutinib (PhIII). This report summarizes application, competitive landscape, commercial potential of novel targets and technologies. For more detail, please read our report released on May 29, 2013, titled, “ASCO ‘13 - Promise of Novel Targets/Technologies to Unfold At ASCO 2013”.
